R-5780
- Generic Name
- R-5780
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Solid Tumor, AdultSolid TumorMelanomaBasal Cell CancerSquamous Cell CancerAdenoma
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Rise Therapeutics LLC
- Target Recruit Count
- 33
- Registration Number
- NCT06398418
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath